Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555456 | 1.00 | DPP4 (0.62) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL878101 | 0.86 | DPP4 (0.75) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL878100 | 0.86 | DPP4 (0.75) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| Hydrochloric Acid SCHEMBL3554659 | 0.85 | DPP4 (0.74) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| Hydrochloric Acid SCHEMBL3554657 | 0.85 | DPP4 (0.74) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL3555458 | 0.77 | DPP4 (0.48) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| Hydrochloric Acid SCHEMBL1223713 | 0.76 | DPP4 (0.98) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL1223814 | 0.74 | DPP4 (0.80) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL556178 | 0.74 | DPP4 (0.84) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL556444 | 0.74 | DPP4 (0.67) | DPP4CHRM1CHRM2CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838528-B2 | Substituted bicyclic 8-pyrrolidinoxanthines, methods for their production, pharmaceutical formulations and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20070167468-A1 | SUBSTITUTED BICYCLIC 8-PYRR0LIDINOXANTHINES, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL FORMULATIONS AND THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167468-A1 | SUBSTITUTED BICYCLIC 8-PYRR0LIDINOXANTHINES, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL FORMULATIONS AND THEIR USE | GPR119, INSR, GCKR | DPP4 568/4885CHRM1 3987/4885CHRM2 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.